New functional activities for the p21 family of CDK inhibitors. J LaBaer, MD Garrett, LF Stevenson, JM Slingerland, C Sandhu, HS Chou, ... Genes & development 11 (7), 847-862, 1997 | 1837 | 1997 |
Microinjection of recombinant p21rho induces rapid changes in cell morphology. HF Paterson, AJ Self, MD Garrett, I Just, K Aktories, A Hall Journal of Cell Biology 111 (3), 1001-1007, 1990 | 922 | 1990 |
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises TA Yap, MD Garrett, MI Walton, F Raynaud, JS de Bono, P Workman Current opinion in pharmacology 8 (4), 393-412, 2008 | 684 | 2008 |
Bcr encodes a GTPase-activating protein for p21rac D Diekmann, S Brill, MD Garrett, N Totty, J Hsuan, C Monfries, C Hall, ... Nature 351 (6325), 400-402, 1991 | 665 | 1991 |
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors TA Yap, LI Yan, A Patnaik, I Fearen, D Olmos, K Papadopoulos, RD Baird, ... Journal of clinical oncology 29 (35), 4688-4695, 2011 | 630 | 2011 |
The ZO-1–associated Y-box factor ZONAB regulates epithelial cell proliferation and cell density MS Balda, MD Garrett, K Matter The Journal of cell biology 160 (3), 423-432, 2003 | 510 | 2003 |
Cell cycle–regulated phosphorylation of p220NPAT by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription T Ma, BA Van Tine, Y Wei, MD Garrett, D Nelson, PD Adams, J Wang, ... Genes & development 14 (18), 2298-2313, 2000 | 431 | 2000 |
CHK2 kinase: cancer susceptibility and cancer therapy–two sides of the same coin? L Antoni, N Sodha, I Collins, MD Garrett Nature Reviews Cancer 7 (12), 925-936, 2007 | 355 | 2007 |
Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors I Collins, MD Garrett Current opinion in pharmacology 5 (4), 366-373, 2005 | 296 | 2005 |
Identification of distinct cytoplasmic targets for ras/R-ras and rho regulatory proteins MD Garrett, AJ Self, C van Oers, A Hall Journal of Biological Chemistry 264 (1), 10-13, 1989 | 291 | 1989 |
The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the … SR Whittaker, MI Walton, MD Garrett, P Workman Cancer research 64 (1), 262-272, 2004 | 260 | 2004 |
GDI1 encodes a GDP dissociation inhibitor that plays an essential role in the yeast secretory pathway. MD Garrett, JE Zahner, CM Cheney, PJ Novick The EMBO journal 13 (7), 1718-1728, 1994 | 255 | 1994 |
Anticancer therapy with checkpoint inhibitors: what, where and when? MD Garrett, I Collins Trends in pharmacological sciences 32 (5), 308-316, 2011 | 241 | 2011 |
Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases M Barvian, DH Boschelli, J Cossrow, E Dobrusin, A Fattaey, A Fritsch, ... Journal of medicinal chemistry 43 (24), 4606-4616, 2000 | 226 | 2000 |
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development DSW Tan, GV Thomas, MD Garrett, U Banerji, JS De Bono, SB Kaye, ... The Cancer Journal 15 (5), 406-420, 2009 | 220 | 2009 |
Regulation of NF‐κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor S Rocha, MD Garrett, KJ Campbell, K Schumm, ND Perkins The EMBO journal 24 (6), 1157-1169, 2005 | 210 | 2005 |
Discovering novel chemotherapeutic drugs for the third millennium MD Garrett, P Workman European Journal of Cancer 35 (14), 2010-2030, 1999 | 203 | 1999 |
CDK inhibition and cancer therapy MD Garrett, A Fattaey Current opinion in genetics & development 9 (1), 104-111, 1999 | 200 | 1999 |
Identification of inhibitors of protein kinase B using fragment-based lead discovery G Saxty, SJ Woodhead, V Berdini, TG Davies, ML Verdonk, PG Wyatt, ... Journal of medicinal chemistry 50 (10), 2293-2296, 2007 | 170 | 2007 |
Cell cycle and biochemical effects of PD 0183812: a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6 DW Fry, DC Bedford, PH Harvey, A Fritsch, PR Keller, Z Wu, E Dobrusin, ... Journal of Biological Chemistry 276 (20), 16617-16623, 2001 | 166 | 2001 |